The stock of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) is a huge mover today! About 619,882 shares traded hands. Regeneron Pharmaceuticals Inc (NASDAQ:REGN) has risen 3.02% since March 9, 2016 and is uptrending. It has underperformed by 4.40% the S&P500.
The move comes after 6 months negative chart setup for the $38.63B company. It was reported on Oct, 12 by Barchart.com. We have $355.60 PT which if reached, will make NASDAQ:REGN worth $1.93 billion less.
Analysts await Regeneron Pharmaceuticals Inc (NASDAQ:REGN) to report earnings on November, 2. They expect $2.27 EPS, down 12.36% or $0.32 from last year’s $2.59 per share. REGN’s profit will be $234.27 million for 41.22 P/E if the $2.27 EPS becomes a reality. After $2.11 actual EPS reported by Regeneron Pharmaceuticals Inc for the previous quarter, Wall Street now forecasts 7.58% EPS growth.
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) Ratings Coverage
Out of 19 analysts covering Regeneron Pharmaceuticals Inc. (NASDAQ:REGN), 9 rate it a “Buy”, 1 “Sell”, while 9 “Hold”. This means 47% are positive. Regeneron Pharmaceuticals Inc. has been the topic of 40 analyst reports since July 28, 2015 according to StockzIntelligence Inc. Chardan Capital Markets downgraded Regeneron Pharmaceuticals Inc (NASDAQ:REGN) rating on Wednesday, March 16. Chardan Capital Markets has “Sell” rating and $325 price target. The rating was initiated by Bernstein with “Outperform” on Wednesday, June 29. Brean Capital reinitiated it with “Buy” rating and $489 target price in Tuesday, March 8 report. The rating was downgraded by Morgan Stanley on Friday, October 2 to “Equal-Weight”. The firm has “Market Perform” rating by Northland Capital given on Wednesday, July 22. The firm has “Outperform” rating given on Monday, July 27 by RBC Capital Markets. The rating was maintained by Leerink Swann on Monday, August 3 with “Outperform”. The stock has “Buy” rating given by UBS on Monday, September 7. The stock of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) has “Outperform” rating given on Thursday, November 5 by RBC Capital Markets. Wells Fargo downgraded the stock to “Market Perform” rating in Wednesday, April 20 report.
According to Zacks Investment Research, “Regeneron Pharmaceuticals Inc. is a biopharmaceutical company that discovers, develops, and intends to commercialize therapeutic drugs for the treatment of serious medical conditions. Regeneron’s platform technologies include Targeted GenomicsTM, FunctionomicsTM, and Designer Protein TherapeuticsTM. Regeneron has drugs in clinical and preclinical development for the potential treatment of obesity, rheumatoid arthritis, cancer, allergies, asthma, amyotrophic lateral sclerosis, constipating conditions, ischemia, and other diseases and disorders. (PRESS RELEASE)”
Insitutional Activity: The institutional sentiment increased to 1.19 in Q2 2016. Its up 0.44, from 0.75 in 2016Q1. The ratio is positive, as 51 funds sold all Regeneron Pharmaceuticals Inc shares owned while 154 reduced positions. 50 funds bought stakes while 193 increased positions. They now own 70.88 million shares or 9.49% less from 78.30 million shares in 2016Q1.
Finemark Bank & Trust Trust holds 0% of its portfolio in Regeneron Pharmaceuticals Inc (NASDAQ:REGN) for 67 shares. Moreover, Integral Derivatives Limited Com has 0.01% invested in Regeneron Pharmaceuticals Inc (NASDAQ:REGN) for 1,700 shares. Cambridge Inv Research holds 0.02% or 2,747 shares in its portfolio. Van Eck holds 0.12% of its portfolio in Regeneron Pharmaceuticals Inc (NASDAQ:REGN) for 69,279 shares. Ballentine Prtnrs Limited Company has 0.02% invested in the company for 638 shares. The Massachusetts-based Alpha Windward Ltd Liability Com has invested 0.07% in Regeneron Pharmaceuticals Inc (NASDAQ:REGN). Founders Ltd Liability, a Connecticut-based fund reported 677 shares. Allianz Asset Mngmt Ag holds 0.02% of its portfolio in Regeneron Pharmaceuticals Inc (NASDAQ:REGN) for 127,814 shares. The Alabama-based Regions Fincl has invested 0.03% in Regeneron Pharmaceuticals Inc (NASDAQ:REGN). Fuller And Thaler Asset, a California-based fund reported 400 shares. Moreover, Glg Llc has 0.12% invested in Regeneron Pharmaceuticals Inc (NASDAQ:REGN) for 4,542 shares. Bessemer Inc accumulated 409 shares or 0% of the stock. The North Carolina-based Piedmont Invest Advsrs Limited Company has invested 0% in Regeneron Pharmaceuticals Inc (NASDAQ:REGN). Public Sector Pension Board holds 0.06% or 14,797 shares in its portfolio. Mariner Invest Group Inc Limited Com holds 1.94% of its portfolio in Regeneron Pharmaceuticals Inc (NASDAQ:REGN) for 16,448 shares.
Insider Transactions: Since May 17, 2016, the stock had 1 buying transaction, and 3 sales for $20.55 million net activity. On Tuesday, May 24 RYAN ARTHUR F sold $396,640 worth of the stock or 1,000 shares. On Tuesday, May 17 the insider Van Plew Daniel P sold $1.70 million. Sanofi bought $23.55M worth of stock or 64,731 shares. $903,125 worth of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) shares were sold by GOLDSTEIN JOSEPH L.
More important recent Regeneron Pharmaceuticals Inc (NASDAQ:REGN) news were published by: Fool.com which released: “Is Another Blockbuster Drug on the Way for Regeneron Pharmaceuticals, Inc.?” on October 10, 2016, also Fool.com published article titled: “Why Investors Are Paying a Premium for Regeneron Pharmaceuticals, Inc.”, Profitconfidential.com published: “Regeneron Pharmaceuticals Inc: 40%+ Returns if REGN Stock Does THIS” on September 23, 2016. More interesting news about Regeneron Pharmaceuticals Inc (NASDAQ:REGN) was released by: Investorplace.com and their article: “A “Don’t Blink” Opportunity In Regeneron Pharmaceuticals Inc (REGN)” with publication date: September 30, 2016.
REGN Company Profile
Regeneron Pharmaceuticals, Inc., incorporated on January 11, 1988, is a biopharmaceutical firm that discovers, invents, develops, makes and commercializes medicines for the treatment of serious medical conditions. The Company’s segment includes activities related to the discovery, development and commercialization of pharmaceutical products for the treatment of serious medical conditions. The Firm commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol and a rare inflammatory condition, and has product candidates in development in other areas of unmet medical need, including oncology, rheumatoid arthritis (RA), asthma, atopic dermatitis, pain and infectious diseases. The Company’s marketed products include EYLEA (aflibercept) injection, Praluent (alirocumab) Injection and ARCALYST (rilonacept) injection for subcutaneous use. The Firm has over 10 product candidates in clinical development. These consist of Trap clinical programs and over 10 human monoclonal antibody product candidates. The Firm has generated each of the antibodies using its VelocImmune technology. The Company’s ARCALYST (rilonacept) Injection for subcutaneous Use is available in the United States for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Auto-inflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS), in adults and children over 12 year.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.